

Title (en)  
HIV AND CANCER TREATMENT

Title (de)  
BEHANDLUNG GEGEN HIV UND KREBS

Title (fr)  
TRAITEMENT DU VIH ET DU CANCER

Publication  
**EP 0954309 A1 19991110 (EN)**

Application  
**EP 97949599 A 19971126**

Priority  
• US 9721564 W 19971126  
• US 4672697 P 19970516

Abstract (en)  
[origin: WO9851303A1] A method of treating HIV or other viral infections by administering a herbicide or fungicide or derivative thereof to an animal or human. The fungicides or herbicides can be used in conjunction with other treatments, e.g. with AZT or protease inhibitors for the treatment of HIV. For example, thiabendazole and chloroprotham have been shown to quickly reduce the level of virus production from cell populations chronically infected with HIV-1 and the antiviral effect is maintained with continued compound exposure. This reduction of virus production occurs at concentrations which are non toxic to the host cell and which have no effect on the syntheses of cellular DNA, RNA and protein. Further, chronically infected cells treated for prolonged periods of time with thiabendazole and chloroprotham were not super-infected with HIV. A method for inhibiting the growth of tumors and cancers in mammals comprising administering a herbicidal or fungicidal derivative is also disclosed herein. The fungicides or herbicides can be used in conjunction with other treatments, e.g. taxol for the treatment of breast cancer. Potentiators can also be included in the herbicidal or fungicidal composition. This method is particularly effective when the cancer or virus is an animal cell genetically modified by plant or fungus genetic material. A chemotherapeutic agent can also be administered first to significantly reduce the size of the cancer and then the treatment with the herbicide or fungicide is used. These methods are particularly effective when the cancer or virus is a mutated cell comprising plant or fungal genetic material.

IPC 1-7  
**A61K 31/41**; **A61K 31/415**; **A61K 31/66**

IPC 8 full level  
**A61K 9/127** (2006.01); **A61K 31/17** (2006.01); **A61K 31/27** (2006.01); **A61K 31/325** (2006.01); **A61K 31/343** (2006.01); **A61K 31/41** (2006.01); **A61K 31/4184** (2006.01); **A61K 31/4196** (2006.01); **A61K 31/427** (2006.01); **A61K 31/662** (2006.01); **A61K 45/00** (2006.01); **A61K 45/06** (2006.01); **A61P 31/12** (2006.01); **A61P 31/18** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP KR)  
**A61K 31/27** (2013.01 - EP); **A61K 31/41** (2013.01 - KR); **A61K 31/4184** (2013.01 - EP); **A61K 31/4196** (2013.01 - EP); **A61K 31/427** (2013.01 - EP); **A61K 31/662** (2013.01 - EP); **A61K 45/06** (2013.01 - EP); **A61P 31/12** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 35/00** (2017.12 - EP)

Citation (search report)  
See references of WO 9851303A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)  
**WO 9851303 A1 19981119**; AR 009968 A1 20000517; AU 7402998 A 19981208; BR 9712981 A 20000418; CA 2268848 A1 19981119; CN 1254281 A 20000524; CO 5070657 A1 20010828; CZ 124999 A3 19990915; EP 0954309 A1 19991110; HU P9904092 A2 20000428; HU P9904092 A3 20000728; IL 129351 A0 20000217; JP 2000510156 A 20000808; KR 20000049064 A 20000725; NO 991701 D0 19990409; NO 991701 L 20000117; PE 11499 A1 19990301; PL 335160 A1 20000410; SK 46999 A3 20000516; TR 199901530 T2 19991021; ZA 979095 B 19980511

DOCDB simple family (application)  
**US 9721564 W 19971126**; AR P970104697 A 19971010; AU 7402998 A 19971126; BR 9712981 A 19971126; CA 2268848 A 19971126; CN 97182189 A 19971126; CO 97065469 A 19971107; CZ 124999 A 19971126; EP 97949599 A 19971126; HU P9904092 A 19971126; IL 12935197 A 19971126; JP 52299798 A 19971126; KR 19997003137 A 19990410; NO 991701 A 19990409; PE 00089497 A 19971009; PL 33516097 A 19971126; SK 46999 A 19971126; TR 9901530 T 19971126; ZA 979095 A 19971010